Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stock Competitors & Peer Comparison

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, VRTX has a market cap of 123.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while VRTX trades at $485.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas VRTX's P/E ratio is 25.80. In terms of profitability, REGN's ROE is +0.14%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, REGN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check VRTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas VRNA's P/E ratio is -102.80. In terms of profitability, REGN's ROE is +0.14%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, REGN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check VRNA's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ARGX has a market cap of 53.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ARGX trades at $860.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ARGX's P/E ratio is 77.67. In terms of profitability, REGN's ROE is +0.14%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, REGN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ARGX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas SGEN's P/E ratio is -57.19. In terms of profitability, REGN's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, REGN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check SGEN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RVMDW has a market cap of 42B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RVMDW trades at $9.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RVMDW's P/E ratio is -2.24. In terms of profitability, REGN's ROE is +0.14%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, REGN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMDW's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RVMD has a market cap of 39.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RVMD trades at $186.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RVMD's P/E ratio is -26.33. In terms of profitability, REGN's ROE is +0.14%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, REGN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMD's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ALNY has a market cap of 35.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ALNY trades at $267.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ALNY's P/E ratio is 48.19. In terms of profitability, REGN's ROE is +0.14%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, REGN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ALNY's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ONC has a market cap of 33.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ONC trades at $312.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ONC's P/E ratio is 69.80. In terms of profitability, REGN's ROE is +0.14%, compared to ONC's ROE of +0.12%. Regarding short-term risk, REGN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ONC's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ROIV has a market cap of 24.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ROIV trades at $34.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ROIV's P/E ratio is -35.47. In terms of profitability, REGN's ROE is +0.14%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, REGN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ROIV's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MRNA has a market cap of 24.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MRNA trades at $61.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MRNA's P/E ratio is -7.59. In terms of profitability, REGN's ROE is +0.14%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, REGN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MRNA's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, INCY has a market cap of 23.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while INCY trades at $117.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas INCY's P/E ratio is 15.68. In terms of profitability, REGN's ROE is +0.14%, compared to INCY's ROE of +0.29%. Regarding short-term risk, REGN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check INCY's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, INSM has a market cap of 23.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while INSM trades at $108.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas INSM's P/E ratio is -18.69. In terms of profitability, REGN's ROE is +0.14%, compared to INSM's ROE of -1.30%. Regarding short-term risk, REGN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check INSM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BNTX trades at $91.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BNTX's P/E ratio is -19.80. In terms of profitability, REGN's ROE is +0.14%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, REGN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BNTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, UTHR has a market cap of 22.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while UTHR trades at $535.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas UTHR's P/E ratio is 19.77. In terms of profitability, REGN's ROE is +0.14%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, REGN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check UTHR's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BGNE's P/E ratio is -22.55. In terms of profitability, REGN's ROE is +0.14%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, REGN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BGNE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, REGN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNA-WT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while GMAB trades at $28.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas GMAB's P/E ratio is 20.66. In terms of profitability, REGN's ROE is +0.14%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, REGN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for REGN.Check GMAB's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, NBIX has a market cap of 17.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while NBIX trades at $170.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas NBIX's P/E ratio is 24.69. In terms of profitability, REGN's ROE is +0.14%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, REGN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check NBIX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ASND trades at $261.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ASND's P/E ratio is -107.85. In terms of profitability, REGN's ROE is +0.14%, compared to ASND's ROE of -56.42%. Regarding short-term risk, REGN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ASND's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BBIO trades at $81.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BBIO's P/E ratio is -21.76. In terms of profitability, REGN's ROE is +0.14%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, REGN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BBIO's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while JAZZ trades at $247.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas JAZZ's P/E ratio is 19.25. In terms of profitability, REGN's ROE is +0.14%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, REGN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for REGN.Check JAZZ's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while EXEL trades at $55.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas EXEL's P/E ratio is 16.74. In terms of profitability, REGN's ROE is +0.14%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for REGN.Check EXEL's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MDGL has a market cap of 12.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MDGL trades at $553.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MDGL's P/E ratio is -43.24. In terms of profitability, REGN's ROE is +0.14%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, REGN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MDGL's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas KRTX's P/E ratio is -28.09. In terms of profitability, REGN's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, REGN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check KRTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while AXSM trades at $230.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas AXSM's P/E ratio is -60.05. In terms of profitability, REGN's ROE is +0.14%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, REGN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check AXSM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BMRN trades at $59.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BMRN's P/E ratio is 28.65. In terms of profitability, REGN's ROE is +0.14%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, REGN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BMRN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TECH trades at $72.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TECH's P/E ratio is 37.18. In terms of profitability, REGN's ROE is +0.14%, compared to TECH's ROE of +0.05%. Regarding short-term risk, REGN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TECH's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RNAM's P/E ratio is -17.39. In terms of profitability, REGN's ROE is +0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, REGN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RNAM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while SMMT trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas SMMT's P/E ratio is -8.63. In terms of profitability, REGN's ROE is +0.14%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, REGN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SMMT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ARWR trades at $74.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ARWR's P/E ratio is -34.56. In terms of profitability, REGN's ROE is +0.14%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, REGN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ARWR's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, KRYS has a market cap of 10.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while KRYS trades at $354.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas KRYS's P/E ratio is 47.44. In terms of profitability, REGN's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, REGN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KRYS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ABVX has a market cap of 10B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ABVX trades at $136.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ABVX's P/E ratio is -71.63. In terms of profitability, REGN's ROE is +0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, REGN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ABVX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CYTK trades at $80.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CYTK's P/E ratio is -13.75. In terms of profitability, REGN's ROE is +0.14%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, REGN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CYTK's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RXDX's P/E ratio is -56.47. In terms of profitability, REGN's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RXDX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while KYMR trades at $115.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas KYMR's P/E ratio is -32.80. In terms of profitability, REGN's ROE is +0.14%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, REGN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KYMR's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, HALO has a market cap of 9.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while HALO trades at $77.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas HALO's P/E ratio is 16.84. In terms of profitability, REGN's ROE is +0.14%, compared to HALO's ROE of +1.26%. Regarding short-term risk, REGN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for REGN.Check HALO's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas NUVL's P/E ratio is -21.79. In terms of profitability, REGN's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, REGN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for REGN.Check NUVL's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while PTGX trades at $140.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas PTGX's P/E ratio is -77.92. In terms of profitability, REGN's ROE is +0.14%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, REGN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PTGX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while IONS trades at $54.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas IONS's P/E ratio is -31.77. In terms of profitability, REGN's ROE is +0.14%, compared to IONS's ROE of -0.59%. Regarding short-term risk, REGN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check IONS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CRNX trades at $83.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CRNX's P/E ratio is -16.35. In terms of profitability, REGN's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, REGN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CRNX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ALKS trades at $52.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ALKS's P/E ratio is 55.49. In terms of profitability, REGN's ROE is +0.14%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, REGN is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ALKS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas IMGN's P/E ratio is -111.55. In terms of profitability, REGN's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, REGN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check IMGN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TGTX trades at $54.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TGTX's P/E ratio is 18.85. In terms of profitability, REGN's ROE is +0.14%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, REGN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TGTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BPMC's P/E ratio is -51.58. In terms of profitability, REGN's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BPMC's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while APGE trades at $134.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas APGE's P/E ratio is -30.95. In terms of profitability, REGN's ROE is +0.14%, compared to APGE's ROE of -0.33%. Regarding short-term risk, REGN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APGE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CERE's P/E ratio is -16.47. In terms of profitability, REGN's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, REGN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CERE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while PCVX trades at $56.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas PCVX's P/E ratio is -8.17. In terms of profitability, REGN's ROE is +0.14%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, REGN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PCVX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while IMVT trades at $40.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas IMVT's P/E ratio is -14.59. In terms of profitability, REGN's ROE is +0.14%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, REGN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IMVT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, IBRX has a market cap of 7.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while IBRX trades at $7.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas IBRX's P/E ratio is -8.76. In terms of profitability, REGN's ROE is +0.14%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, REGN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IBRX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MTSR's P/E ratio is -23.58. In terms of profitability, REGN's ROE is +0.14%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, REGN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MTSR's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RYTM trades at $106.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RYTM's P/E ratio is -34.06. In terms of profitability, REGN's ROE is +0.14%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, REGN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RYTM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MRUS's P/E ratio is -17.05. In terms of profitability, REGN's ROE is +0.14%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, REGN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRUS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ACLX's P/E ratio is -28.27. In terms of profitability, REGN's ROE is +0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, REGN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ACLX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while COGT trades at $39.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas COGT's P/E ratio is -18.52. In terms of profitability, REGN's ROE is +0.14%, compared to COGT's ROE of -0.83%. Regarding short-term risk, REGN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check COGT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while PRAX trades at $314.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas PRAX's P/E ratio is -23.51. In terms of profitability, REGN's ROE is +0.14%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, REGN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PRAX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RETA's P/E ratio is -66.29. In terms of profitability, REGN's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, REGN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RETA's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while PTCT trades at $78.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas PTCT's P/E ratio is -33.73. In terms of profitability, REGN's ROE is +0.14%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, REGN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for REGN.Check PTCT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CGON trades at $71.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CGON's P/E ratio is -30.84. In terms of profitability, REGN's ROE is +0.14%, compared to CGON's ROE of -0.23%. Regarding short-term risk, REGN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CGON's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while SRRK trades at $52.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas SRRK's P/E ratio is -14.72. In terms of profitability, REGN's ROE is +0.14%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, REGN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SRRK's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CNTA's P/E ratio is -22.63. In terms of profitability, REGN's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, REGN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CNTA's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while LGND trades at $303.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas LGND's P/E ratio is 36.38. In terms of profitability, REGN's ROE is +0.14%, compared to LGND's ROE of +0.16%. Regarding short-term risk, REGN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for REGN.Check LGND's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while SYRE trades at $100.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas SYRE's P/E ratio is -48.11. In terms of profitability, REGN's ROE is +0.14%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, REGN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SYRE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while BLTE trades at $150.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas BLTE's P/E ratio is -80.26. In terms of profitability, REGN's ROE is +0.14%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, REGN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BLTE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MIRM trades at $118.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MIRM's P/E ratio is -8.73. In terms of profitability, REGN's ROE is +0.14%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, REGN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MIRM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ERAS has a market cap of 6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ERAS trades at $19.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ERAS's P/E ratio is -20.61. In terms of profitability, REGN's ROE is +0.14%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, REGN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ERAS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CDTX's P/E ratio is -19.77. In terms of profitability, REGN's ROE is +0.14%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, REGN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CDTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, REGN's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, REGN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ABCM's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ISEE's P/E ratio is -22.44. In terms of profitability, REGN's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, REGN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ISEE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, XENE has a market cap of 5.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while XENE trades at $68.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas XENE's P/E ratio is -14.52. In terms of profitability, REGN's ROE is +0.14%, compared to XENE's ROE of -0.49%. Regarding short-term risk, REGN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check XENE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TVTX trades at $56.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TVTX's P/E ratio is -257.77. In terms of profitability, REGN's ROE is +0.14%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, REGN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TVTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas APLS's P/E ratio is 38.35. In terms of profitability, REGN's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APLS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while DFTX trades at $44.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas DFTX's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, REGN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DFTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TERN's P/E ratio is -51.41. In terms of profitability, REGN's ROE is +0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, REGN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TERN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CAI trades at $16.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CAI's P/E ratio is -90.70. In terms of profitability, REGN's ROE is +0.14%, compared to CAI's ROE of +0.06%. Regarding short-term risk, REGN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CAI's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MANE trades at $111.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MANE's P/E ratio is -35.47. In terms of profitability, REGN's ROE is +0.14%, compared to MANE's ROE of -0.84%. Regarding short-term risk, REGN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MANE's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CRSP trades at $47.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CRSP's P/E ratio is -9.35. In terms of profitability, REGN's ROE is +0.14%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, REGN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CRSP's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas FOLD's P/E ratio is -161.00. In terms of profitability, REGN's ROE is +0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, REGN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for REGN.Check FOLD's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas AKRO's P/E ratio is -14.57. In terms of profitability, REGN's ROE is +0.14%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, REGN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for REGN.Check AKRO's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ALPN's P/E ratio is -101.52. In terms of profitability, REGN's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, REGN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ALPN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while DNTH trades at $105.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas DNTH's P/E ratio is -25.57. In terms of profitability, REGN's ROE is +0.14%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, REGN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNTH's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ACAD trades at $25.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ACAD's P/E ratio is 12.55. In terms of profitability, REGN's ROE is +0.14%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, REGN is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ACAD's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CELC trades at $88.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CELC's P/E ratio is -22.66. In terms of profitability, REGN's ROE is +0.14%, compared to CELC's ROE of -2.45%. Regarding short-term risk, REGN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CELC's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while VKTX trades at $37.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas VKTX's P/E ratio is -8.96. In terms of profitability, REGN's ROE is +0.14%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, REGN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check VKTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while EWTX trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas EWTX's P/E ratio is -23.95. In terms of profitability, REGN's ROE is +0.14%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, REGN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check EWTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas OPT's P/E ratio is -1.52. In terms of profitability, REGN's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, REGN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for REGN.Check OPT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas MRTX's P/E ratio is -4.82. In terms of profitability, REGN's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, REGN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRTX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while LEGN trades at $22.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas LEGN's P/E ratio is -32.74. In terms of profitability, REGN's ROE is +0.14%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, REGN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check LEGN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while DYN trades at $23.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas DYN's P/E ratio is -7.37. In terms of profitability, REGN's ROE is +0.14%, compared to DYN's ROE of -0.58%. Regarding short-term risk, REGN is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DYN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CPRX's P/E ratio is 12.30. In terms of profitability, REGN's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, REGN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CPRX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, NAMSW has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while NAMSW trades at $20.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas NAMSW's P/E ratio is -11.36. In terms of profitability, REGN's ROE is +0.14%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, REGN is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for REGN.Check NAMSW's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ELVN trades at $53.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ELVN's P/E ratio is -31.86. In terms of profitability, REGN's ROE is +0.14%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, REGN is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ELVN's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas RYZB's P/E ratio is -57.86. In terms of profitability, REGN's ROE is +0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, REGN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RYZB's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas CBAY's P/E ratio is -32.81. In terms of profitability, REGN's ROE is +0.14%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, REGN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CBAY's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while NAMS trades at $31.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas NAMS's P/E ratio is -19.92. In terms of profitability, REGN's ROE is +0.14%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to NAMS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check NAMS's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while DNLI trades at $23.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas DNLI's P/E ratio is -8.09. In terms of profitability, REGN's ROE is +0.14%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, REGN is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNLI's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ADPT has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ADPT trades at $22.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ADPT's P/E ratio is -42.44. In terms of profitability, REGN's ROE is +0.14%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, REGN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ADPT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while ARQT trades at $28.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas ARQT's P/E ratio is -949.67. In terms of profitability, REGN's ROE is +0.14%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, REGN is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ARQT's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TNGX trades at $28.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TNGX's P/E ratio is -34.33. In terms of profitability, REGN's ROE is +0.14%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, REGN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TNGX's competition here

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, REGN stands at 69.7B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, REGN is priced at $676.69 on the NASDAQ, while TLX trades at $10.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

REGN currently has a P/E ratio of 14.83, whereas TLX's P/E ratio is -568.48. In terms of profitability, REGN's ROE is +0.14%, compared to TLX's ROE of -0.02%. Regarding short-term risk, REGN is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TLX's competition here